New targeted drug shows promise for Hard-to-Treat cancers
NCT ID NCT05002270
First seen Jan 15, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study tested a new drug called JAB-21822, alone or with another drug (cetuximab), in 29 adults with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal was to check safety and how well the drug works. Participants had already tried at least one standard treatment. The study found the drug's side effects and measured tumor shrinkage, but ongoing treatment is needed to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinc
Phoenix, Arizona, 85054, United States
-
Mayo Clinc
Scottsdale, Arizona, 85259, United States
-
Mayo Clinc
Jacksonville, Florida, 32224, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.